Author

Hanmeng Qi

Beijing Institute for Stem Cell and Regenerative MedicinePrimary ORCID profile (0009-0007-5016-6841 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Hanmeng QiiD1 paper · Beijing Institute for Stem Cell and Regenerative Medicine

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1

Frequent Co-Authors

Chengxiang XiaiD· 3 shared Dehao HuangiD· 3 shared Fangxiao HuiD· 3 shared Jiaxin WuiD· 3 shared Jinyong WangiD· 3 shared Leqiang ZhangiD· 3 shared Mengyun ZhangiD· 3 shared Qitong WengiD· 3 shared

Activity by Year

2025-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Chengxiang XiaORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CD33KO-CD33-mesothelin loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia

Yao Wang, Xiujuan Zheng, Zhiqian Wang, Ziyun Xiao, Yunqing Lin, Fan Zhang, Yanhong Liu, Pengcheng Liu, Qitong Weng, Leqiang Zhang, Chengxiang Xia, Dehao Huang, Lijuan Liu, Yanping Zhu, Qi Zhang, , Jinyong Wang

This study designs a CD33-mesothelin loop CAR to enhance iNK cell efficacy against AML by avoiding fratricide and improving cytotoxicity.

Journal for ImmunoTherapy of Cancer · Sep 1, 2025Peer-reviewedCancer Biology

Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies

Yunqing Lin, Ziyun Xiao, Fangxiao Hu, Xiujuan Zheng, Chenyuan Zhang, Yao Wang, Yanhong Liu, Dehao Huang, Zhiqian Wang, Chengxiang Xia, Qitong Weng, Leqiang Zhang, Yaoqin Zhao, Hanmeng Qi, Yiyuan Shen, , Jinyong Wang

This study generates CD7 CAR-NK cells from pluripotent stem cells that avoid fratricide and effectively suppress T-cell malignancies in xenograft models.

Journal of Hematology & Oncology · May 19, 2025Peer-reviewedCancer Biology

Pluripotent stem cell-derived NK progenitor cell therapy prevents tumour occurrence and eradicates minimal residual disease

Zhiqian Wang, Yunqing Lin, Dehao Huang, Leqiang Zhang, Chengxiang Xia, Qitong Weng, Yanhong Liu, Tongjie Wang, Mengyun Zhang, Jiaxin Wu, Hanmeng Qi, Lijuan Liu, Yiyuan Shen, Yi Chen, Yanping Zhu, , Jinyong Wang

This study develops a novel CAR-NK cell therapy using pluripotent stem cell-derived NK progenitors that persist in blood and eliminate minimal residual disease.

bioRxiv · Jan 7, 2025 · PreprintCancer Biology